# Advanced Hepatocellular Carcinoma FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/advanced-hepatocellular-carcinoma

> No upcoming FDA catalysts in advanced Hepatocellular Carcinoma; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for advanced Hepatocellular Carcinoma?

No upcoming FDA catalysts in advanced Hepatocellular Carcinoma; 3 past events are recorded. ClinicalTrials.gov: "NCT04740307 (Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-23." [Calendar and source filings](https://sec-api.dev/indications/advanced-hepatocellular-carcinoma)

Source: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT04740307?tab=results (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/indications/advanced-hepatocellular-carcinoma#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 29, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Hepatocellular Carcinoma | completed | "NCT04740307 (Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04740307)) |
| March 30, 2026 | [Imfinzi® (durvalumab) primary completion](https://sec-api.dev/pdufa/durvalumab) | AZN | Advanced Hepatocellular Carcinoma | completed | "NCT05883644 (Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-30 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05883644)) |
| June 23, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Hepatocellular Carcinoma | completed | "NCT04740307 (Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04740307?tab=results)) |

## Drugs

- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Imfinzi® (durvalumab)](https://sec-api.dev/pdufa/durvalumab) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/advanced-hepatocellular-carcinoma.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Advanced Hepatocellular Carcinoma FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/advanced-hepatocellular-carcinoma

```bibtex
@misc{secapidev_indications_advanced_hepatocellular_carcinoma_20261116,
  title        = {Advanced Hepatocellular Carcinoma FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/advanced-hepatocellular-carcinoma}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_advanced_hepatocellular_carcinoma_20261116","title":"Advanced Hepatocellular Carcinoma FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/advanced-hepatocellular-carcinoma","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
